Recognition of a glycosylation substrate by the O-GlcNAc transferase TPR repeats. by Rafie, K. et al.
rsob.royalsocietypublishing.orgResearch
Cite this article: Rafie K, Raimi O, Ferenbach
AT, Borodkin VS, Kapuria V, van Aalten DMF.
2017 Recognition of a glycosylation substrate
by the O-GlcNAc transferase TPR repeats. Open
Biol. 7: 170078.
http://dx.doi.org/10.1098/rsob.170078Received: 30 March 2017
Accepted: 2 June 2017Subject Area:
biochemistry/structural biology
Keywords:
glycosylation, signalling, O-GlcNAc, O-GlcNAc
transferase, substrate recognitionAuthor for correspondence:
Daan M. F. van Aalten
e-mail: dmfvanaalten@dundee.ac.uk†These authors contributed equally to this
study.
Electronic supplementary material is available
online at https://dx.doi.org/10.6084/m9.
figshare.c.3803632.& 2017 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.Recognition of a glycosylation substrate
by the O-GlcNAc transferase TPR repeats
Karim Rafie1,†, Olawale Raimi1,†, Andrew T. Ferenbach1, Vladimir S. Borodkin1,
Vaibhav Kapuria2 and Daan M. F. van Aalten1
1Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee, UK
2Center for Integrative Genomics, University of Lausanne 1015, Switzerland
DMFvA, 0000-0002-1499-6908
O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-
translational modification found on hundreds of nucleocytoplasmic proteins
in metazoa. Although a single enzyme, O-GlcNAc transferase (OGT), gener-
ates the entire cytosolic O-GlcNAc proteome, it is not understood how it
recognizes its protein substrates, targeting only a fraction of serines/
threonines in the metazoan proteome for glycosylation. We describe a
trapped complex of human OGT with the C-terminal domain of TAB1,
a key innate immunity-signalling O-GlcNAc protein, revealing extensive
interactions with the tetratricopeptide repeats of OGT. Confirmed by muta-
genesis, this interaction suggests that glycosylation substrate specificity is
achieved by recognition of a degenerate sequon in the active site combined
with an extended conformation C-terminal of the O-GlcNAc target site.1. Introduction
The attachment of a single b-N-acetylglucosamine (O-GlcNAc) sugar onto
serine and threonine residues of nucleocytoplasmic proteins is a dynamic and
abundant post-translational modification found in higher eukaryotes [1–3].
Remarkably, this modification is regulated by only two antagonistic enzymes:
the O-GlcNAc transferase (OGT), which transfers the GlcNAc moiety onto
acceptor residues from the donor sugar nucleotide UDP-GlcNAc, and the
O-GlcNAc hydrolase (OGA), which removes it. To date more than 1000
O-GlcNAc proteins have been identified by mass spectrometry [4–10]. These
proteins cover a wide range of cellular processes such as transcription and
translation [11–13], trafficking and localization [14,15], as well as cell cycle pro-
gression [16–19]. However, it remains unclear how a single OGT enzyme is able
to specifically recognize a limited number of serines/threonines on such a large
number of substrates.
OGT is a multi-domain protein with a catalytic core at the C-terminus and
13 tetratricopeptide (TPR) repeats at the N-terminus, making up about half of
the enzyme. Early experiments suggested that the TPR domain is involved in
substrate recognition and/or protein–protein interactions [20–27]. The struc-
ture of the isolated OGT TPR domain revealed topological similarity to other
helical repeat proteins and led to speculation that this domain might bind sub-
strates in an extended conformation [20]. The first structural insights into the
OGT catalytic domain came from an OGT orthologue in the bacterium Xantho-
monas campestris [28,29]. This structure revealed that the sugar donor binding
site is made up of the two lobes of the glycosyl transferase B (GT-B) fold, tightly
fused to the superhelical TPR domain [28]. The subsequent structure of human
OGT [30] revealed a very similar fold with the addition of an intervening
domain of unknown function between the two catalytic lobes [30]. The struc-
ture suggested an ordered bi-bi mechanism of substrate binding, in which
UDP-GlcNAc binds before the acceptor substrate [30]. Initial structural studies
exploring Michaelis/substrate complexes with short acceptor peptides have
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2revealed limited substrate interactions with the enzyme
[31,32]. More recently, Pathak et al. investigated the common
binding modes of acceptor peptides to OGT [33]. Starting
from a peptide library, they identified preference for certain
acceptor peptide sequences, leading to definition of a degen-
erate sequon of OGT peptide substrates ([TS][PT][VT][S/
T][RLV][ASY]). Crystal structures of complexes of OGT with
some of these peptides revealed that OGT binds all the accep-
tor peptides studied so far in an extended conformation with
similar conformation of the residues in the 23 to þ2 position
around the acceptor serine/threonine. Although the C-termini
of these peptides point towards the TPR domain, these
structural data do not explain how OGT recognizes larger
protein substrates for glycosylation. The short sequence
patterns alone are not sufficient to accurately predict the
O-GlcNAc proteome, suggesting other mechanisms contribute
to substrate recognition.
A clue to how this might work came from the unusual
OGT substrate host cell factor 1 (HCF1). HCF1 is a ubiqui-
tously expressed chromatin-associated protein and a major
transcriptional co-regulator involved in numerous cellular
processes such as cell cycle progression (reviewed in [34]),
which has also been shown to be heavily O-GlcNAcylated
[35]. HCF1 is initially expressed as an approximately
210 kDa protein that is activated by limited proteolysis (pro-
tease maturation) within the proteolytic processing domain
(PPD), consisting of multiple 20-residue repeats [36,37]. Strik-
ingly, in 2011 it was discovered that OGT not only
glycosylates HCF1 but is also needed for its proteolytic matu-
ration [13,35]. A depletion of OGT leads to an accumulation
of full-length HCF1 protein and the PPD is proteolytically
cleaved by OGT via an unusual glycosylated glutamate inter-
mediate [24,35,38]. A recent structural study of a short PPD
(HCF1PRO) repeat in complex with OGT revealed that part
of the substrate bound in extended conformation in the
TPR repeats [24]. OGT was shown to form an extensive
array of polar interactions with the backbone of the
HCF1PRO repeat peptide, as well as specific side chain inter-
actions that were demonstrated to be essential for HCF1PRO
binding [24]. However, it is as yet not clear if this binding
mode also extends to OGT glycosylation substrates.
A well-characterized OGT glycosylation substrate is the
TGFb-activated kinase 1 (TAK1) binding protein 1 (TAB1), a
pseudophosphatase involved in the TGFb-mediated inflam-
matory signalling pathway and found to be an essential
activator of TAK1 [39,40]. The structure of the TAB1 N-term-
inal pseudophosphatase domain has been reported and
revealed similarity to the PPM family of protein Ser/Thr
protein phosphatases [41]. Previous studies have shown
that phosphorylation at a C-terminal region of TAB1 regulates
TAK1 activity [42–44]. We have recently discovered that TAB1
is dynamically O-GlcNAcylated at Ser395 in the C-terminal
domain [45]. This glycosylation appears to be required for
full activity of TAK1 and activation of downstream transcrip-
tion and secretion of pro-inflammatory cytokines. Here, we
exploit a novel approach to covalently trap OGT-substrate
complexes to explore how OGT recognizes glycosylation sub-
strates through its TPR domain. The structure of the OGT in
complex with the TAB1 C-terminal domain combined with
mutagenesis studies reveals that OGT recognizes the TAB1
substrate, and by extension a group of glycosylation substrates
with similar disordered regions, through extensive essential
interactions with the TPR repeats.2. Results and discussion
2.1. The TAB1 O-GlcNAc site resides in a disordered
region with similarity to other OGT targets
TheO-GlcNAcylation sites on theOGTsubstrates TAB1 [45], col-
lapsin response mediator 2 protein (CRMP2) [9] and casein
kinase 2 (CK2) [46] are located in disordered regions close to
the C-terminus (figure 1a). Although short peptides derived
from these sites can be co-crystallized with OGT [31–33], we
have been unsuccessful in using this approach with longer
sequences/intact proteins to explore the role of the OGT TPR
domain in substrate recognition. Aligning the sequences
around the O-GlcNAc sites reveals similarities near the site of
modification (figure 1b). Remarkably, this is also similar to
the proteolytic cleavage site of a HCF1PRO repeat, with the
major difference being a glutamate at the acceptor position
(figure 1b). Mutating this glutamate to a serine is sufficient to
change thepeptide fromaproteolytic to aglycosylationsubstrate
[24]. In the OGT:HCF1PRO structure [24], the peptide substrate
spans thewhole length of the TPR domain (figure 2b). The pep-
tide interacts with the TPRs through some of its side chains, but
intriguingly five regularly spaced asparagine side chains inOGT
form hydrogen bonds with the HCF1PRO peptide backbone
in a sequence-independent manner (figure 2b). We noted the
fortuitous proximity of the HCF1PRO C-terminus to the OGT
N-terminus (CaHCF1–1340-CaOGT313 approx. 12 A˚; figure 2b),
and wondered whether this would enable the direct tethering
of substrates to OGT via a fusion linker to allow us to explore
OGT-glycosylation substrate complexes.
2.2. A linear fusion of OGT and HCF1PRO reproduces
the HCF1PRO binding mode
To explorewhether a fusion of theC-terminus of a peptide sub-
strate to the N-terminus of a truncated OGT (312–1031) would
generate physiological OGT-substrate complexes, we explored
this approach first with HCF1PRO. A construct was designed
where an 18-mer HCF1PRO repeat peptide (PPCETHETGTTN
TATTAT) was fused to the N-terminal Thr315 of OGT via
a three glycine (3xGly) linker (figure 2a). The fusion
construct was overexpressed as a His6-tagged protein in
E. coli, purified and crystallized. Well-diffracting protein crys-
tals were obtained and synchrotron data were collected to
1.9 A˚ (electronic supplementary material, table S1). Molecular
replacement and subsequent refinement revealed continuous
unbiased jFoj– jFcj density for both the HCF1PRO peptide and
the 3xGly linker (figure 2b). Encouragingly, the conformation
of the HCF1PRO peptide in the fusion protein was nearly iden-
tical to that observed in the previously published OGT-HCF1
peptide complex [24] (RMSD on Ca atoms ¼ 0.2 A˚). Thus,
just as with the free peptide, the tethered HCF1PRO peptide
backbone binds the OGT TPR domain in an extended confor-
mation, interacting with residues lining the concave surface
of the TPR superhelix (figure 2b). Therefore, a linear fusion of
OGT and HCF1PRO reproduces the HCF1PRO binding mode.
2.3. A linear TAB1:OGT fusion suggests that TAB1 makes
extensive interactions with the OGT TPRs
We next explored the OGT-substrate fusion approach as
a means of trapping complexes of OGT with TAB1. We
PPC2-like domain
1
5 366
504
1 572
64 453
dehydropyrimidase domain
5 328
kinase domain
1 391
TAB1
CRMP2
CK2
V P Y S S A Q S T S K T S V T L S L
T P A S S A K T S P A K Q Q A P P V
T P V S S A N M M S G I S S V P T P
P P C E T H E T G T T N T A T T A T
TAB1
CRMP2
CK2
HCF1
409
531
361
1095
392
514
344
1078
(a)
(b)
517
395
347
(c)
catalytic domain
TPR domain
HCF1 peptide
Figure 1. O-GlcNAc sites for a subset of proteins are located in a C-terminal disordered domain. (a) Cartoon depicting the domain structure and location of the
glycosylation sites of the three OGT substrates TAB1, CRMP2 and CK2. The O-GlcNAc sites are depicted as blue hexagons. (b) Sequence alignment of the O-GlcNAc
sites of TAB1, CRMP2 and CK2 as well as an HCF1PRO repeat. The O-GlcNAc sites for TAB1, CRMP2 and CK2, as well as the corresponding glutamate for the HCF1PRO
repeat are highlighted with a black box. The sequence alignment shows the similarity between TAB1, CK2, CRMP2 and HCF1 surrounding the O-GlcNAc sites.
(c) Schematic of OGT with a bound HCF1 peptide. The catalytic domain is shown in blue; the tetratricot-peptide repeat domain is shown in grey and the
HCF1 peptide as yellow sticks (PDBID 4N3B).
rsob.royalsocietypublishing.org
Open
Biol.7:170078
3generated a TAB1:OGT fusion construct matching the
HCF1PRO:OGT fusion, using an 18-mer TAB1 peptide derived
from the S395 glycosylation site (VPYSSAQSTSKTSVTLSL;
figure 2a). The chimaeric protein was overexpressed as a
His6-fusion construct in E. coli and purified as described for
the HCF1PRO:OGT fusion protein (figure 2a). We were able
to generate crystals of the TAB1:OGT fusion protein, solve
the structure by molecular replacement and refine the com-
plex against 2.5 A˚ synchrotron diffraction data to Rwork/
Rfree ¼ 0.22/0.25 (electronic supplementary material, table
S1). The unbiased jFoj– jFcj density allowed unambiguous
building of the linker and peptide (figure 2b). The first
eight amino acids of the TAB1 peptide (VPYSSAQS),
covering the glycosylation site, were found in a similar
conformation in the active site to the free TAB1 peptide in
complex with OGT reported previously [31] (figure 2b,
RMSD on Cas ¼ 1.4 A˚). The electron density revealed
Ser395 to be glycosylated as a result of self-glycosylation
during expression in E. coli, which was confirmed by western
blot analysis (figure 3a). The sugar occupies the same position
as observed in a complex with a short synthetic TAB1
glycopeptide [31] (maximum atomic shift ¼ 0.1 A˚). Intrigu-
ingly, there appears to be some extra electron density
near Ser396 and Ser399 suggestive of additional glycosyla-
tion sites (electronic supplementary material, figure S1)
that could be an artefact of the very high (local) concen-
trations of the fused substrate peptide, or glycosylation
occurring in trans as a result of the high proteinconcentrations (approx. 10 mg ml21) used in the crystalliza-
tion experiments. In the TAB1:OGT fusion structure, the
TAB1 peptide forms two side-chain-mediated interactions
(Ser404/Thr406) with the TPR domain of OGT (Asp386/
Asp420) (figure 2b). These are remarkably similar to the inter-
actions between the same OGT residues and Thr1090 and
Thr1092 of the HCF1PRO repeat (figure 2b). Similarly, the
interactions between the TAB1/HCF1 peptide backbones
and the five regularly spaced OGT TPR asparagines are con-
served (figure 2b). Furthermore, the overall conformations of
the TAB1 and HCF1 peptides in the respective fusion
constructs is similar (RMSD on Cas ¼ 1.3 A˚). Thus, a linear
TAB1:OGT fusion suggests that the TAB1 OGT substrate
makes extensive interactions with the OGT TPRs.2.4. Interactions with the OGT TPRs contribute to TAB1
O-GlcNAcylation
Although the similarity to the HCF1 peptide binding mode
and the presence of glycosylation on Ser395 suggests we
have trapped a physiologically relevant TAB1:OGT complex,
we further tested this model by structure-guided site-directed
mutagenesis in the context of truncated OGT (312–1031) and
TAB1 (7–409) as separate proteins. Two types of OGT
mutants were generated: a single-point mutant in the active
site (K842M), known to be essential for catalytic activity
[31] and a quintuple mutant where the five key asparagine
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Figure 2. Design and structures of OGT:substrate fusion proteins. (a) Partial sequence of the fusion proteins showing the His6-tag, the sequence of the substrate
peptide, the 3xGly linker and the start of the OGT protein. Construct boundaries are indicated. The reported O-GlcNAc site Ser395 on TAB1 [45] is highlighted with a
red arrow. Visible residues in the respective fusion construct structures are highlighted by a green box. (b) Three panels showing the structures of the free HCF1PRO
repeat (PDBID 4N39) bound to OGT (i), the fusion protein HCF1PRO:OGT (ii) and the fusion protein TAB1:OGT (iii). OGT is shown in cartoon representation with the
TPR and catalytic domains in grey and blue, respectively. The substrate peptides, UDP and the GlcNAc residues are shown as yellow, black and pink sticks, respect-
ively. The 3xGly linker in the fusion constructs is shown as green sticks. OGT residues interacting with the backbone of the substrate peptide are shown as magenta
sticks and residues interacting with side chains are shown as orange sticks. The catalytically important K842 residue is shown as orange sticks. The green labels
highlight the start and end residues of the substrate part of the fusion constructs. The distance from the N-terminus of OGT and the C-terminus of the free HCF1PRO
peptide (top) is shown as a black double-headed arrow. Polar interactions between OGT and the backbone and side chains of substrate peptides are shown as black
and blue dashed lines, respectively. The Fo2Fc map for the fusion constructs HCF1PRO:OGT and TAB1:OGT are shown as light-blue mesh contoured to 2.5 s.
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4residues that form the bulk of interactions in the TPR domain
(Asn322, Asn325, Asn356, Asn390 and Asn424, figure 2b)
were all mutated to alanines (from here on referred to as
the 5N5A mutant). Based on the TAB1:OGT fusion protein
complex, the 5N5A mutations would be expected to disrupt
the binding of the C-terminal region of TAB1 to the TPR
domain. Using western blot analysis, we probed OGT activity
on TAB1 and blotted for O-GlcNAcylation using an
O-GlcNAc Ser395 specific antibody [45]. As demonstrated
previously, TAB1 is readily O-GlcNAcylated by WT OGT,
whereas no glycosylation is observed with the catalytically
inactive K842M mutant [31] (figure 3c). The 5N5A mutant
shows significantly reduced activity on a free TAB1 peptide(KKPVSVPYSSAQSTSKTSVTLSL) matching the peptide
used in the fusion construct (figure 3b), in agreement with
the interactions formed by the key asparagines in the TPR
domain of OGT observed in the structure (figure 2b). How-
ever, when using a shorter synthetic TAB1 peptide
(KKPVSVPYSSAQSTS, ending just before the start of the
TPR repeats), the 5N5A mutant shows the same activity
levels as WT OGT (electronic supplementary material,
figure S2a). Intriguingly, the 5N5A mutant appears to show
a more modest reduction of glycosyltransferase activity
(approx. 50%), as calculated by quantifying fluorescent
signal from the fluorophore conjugated secondary antibodies
used in the western blot analysis (electronic supplementary
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Figure 3. Activity of wild-type and mutant OGT on peptide and protein substrates. (a) Western blot analysis of CpOGA treated purified TAB1:OGT fusion protein.
Briefly, 0.5 mg of TAB1:OGT was incubated in the presence and absence of approximately 10 mg ml21 CpOGA for 30 min at 378C. Reactions were stopped by
addition of LDS-loading buffer and boiling at 958C. (b) Graph showing the steady-state kinetics to determine the KM of the TAB1 peptide (KKPVSVPYSSAQSTS
KTSVTLSL). Briefly, 50 nM hOGT(WT/5N5A) was pre-incubated with varying concentrations of TAB1 peptide before starting the reaction by adding UDP-GlcNAc
to a final concentration of 50 mM. The reaction was stopped before 10% of substrate was converted by addition of detection reagent in 50% MeOH. KM
(WT) ¼ 42+ 7 mM, KM (5N5A) ¼ N.D. (c) Western blot analysis of in vitro glycosylation reactions of TAB1 with OGT (WT/mutants). Briefly, 10 mM TAB1
protein was incubated with 50 nM hOGT in 100 ml 0.1 M Tris-HCl pH 7.4, 0.15 M NaCl, 0.5 mM TCEP buffer. Reactions were started by the addition of UDP-GlcNAc
to a final concentration of 100 mM and incubated at 258C. Samples were taken at indicated time points and reactions stopped by boiling for 5 min at 958C in
LDS-loading buffer.
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5material, figure S2b), on the TAB1 (7–409) protein (figure 3c),
suggesting that while interactions of the TAB1 C-terminus
with the OGT TPRs are important, further interactions with
the globular pseudophosphatase domain of TAB1 may
exist. Nevertheless, interactions with the OGT TPRs
contribute to TAB1 O-GlcNAcylation.
3. Concluding remarks
The human O-GlcNAc transferase is a multi-domain protein
and is essential in metazoa [12,47,48]. However, it is still
unclear how a single OGT enzyme recognizes its multitude
of substrates. Previous work has proposed sequence speci-
ficity targeting 22 to þ3 relative to the acceptor residue
[33,49]. Previous work has also suggested the involvement
of the TPR domain in substrate recognition by incrementally
removing repeats from the TPR domain, resulting in a loss of
activity on substrates even on a peptide level, although the
molecular basis of this was as yet unclear [20–23,25–27].
Using the proteolytic OGT substrate HCF1, Lazarus et al.
[24] revealed the involvement of multiple OGT residues onthe concave surface of the TPR domain in binding side
chains and backbone of the HCF1PRO repeat proteolytic sub-
strate. Here, we used a fusion approach to trap OGT-substrate
complexes to investigate the role of the TPRs in recognition of
glycosylation substrates. We first demonstrated that this
fusion approach recapitulates the published HCF1PRO
peptide binding mode and then used that to reveal how the
C-terminus of the OGT glycosylation substrate TAB1 is recog-
nized by the enzyme. The TAB1 C-terminus binds in an
extended conformation in the TPR domain, making extensive
contacts with the concave surface through regularly spaced
asparagines in OGT. An OGT mutant lacking these aspara-
gines was deficient in glycosylation of TAB1. Interestingly,
the data show a complete loss of O-GlcNAcylation of a free
TAB1 C-terminal peptide, whereas activity on a TAB1 protein
is more modestly reduced. These findings, coupled with
recently published work on an OGT substrate sequence
preference [33], suggest that OGT may bind its substrates
through a combination of mechanisms. It is interesting to
note that many other OGT substrates (e.g. Casein kinase II
and CRMP2; figure 1a) also possess similarly disordered
rsob.royalsocietypublishing.org
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6regions C-terminal of the O-GlcNAcylation site, suggesting
that this may be a general mode of OGT substrate recog-
nition. However, O-GlcNAc sites have also been reported to
reside in/close to secondary structure motifs, as is the case
for Histone H2B [50], p53 [51], the glucose-6-phosphate dehy-
drogenase G6PD [52] and SNAP-29 [53]. It is possible that a
subset of substrates is O-GlcNAcylated in a co-translational
fashion as proposed by recent work [54]. In this work, we
have shown, using crystallography and site-directed muta-
genesis, that the OGT substrate TAB1 binds the enzyme in
the same way as the proteolytic substrate HCF1 [24] and
that the five asparagine residues found on the concave sur-
face of the TPR domain (Asn321, Asn322, Asn356, Asn390
and Asn424) are important for binding. Future studies
could be directed at dissecting which other parts of OGT
and/or substrate proteins contribute to substrate binding.00784. Material and methods
4.1. Construct design/cloning
A codon-optimized version of hOGT 313–1031, based on the
boundaries described in [31], was ordered from GenScript
and cloned as a BamHI-NotI restriction fragment into a
modified version of pGEX6P1 containing a 6His tag instead
of a GST tag. PCR primers (6H_HCF1_GGG_hOGT_fwd
GTATTCATGCATCATCACCACCATCACccgccctgcgagacccacg,
6H_HCF1_GGG_hOGT_rev CAGGTTGTTCAGGGAATCAG
CATGGGTaccgccaccggtggcggtggtggcggtg; 6H_TAB1_GGG
_hOGT_fwd GTATTCATGCATCATCACCACCATCACGTG
CCATACTCCAGCGCCCAG and 6H_TAB1_GGG_hOG
T_rev CAGGTTGTTCAGGGAATCAGCATGGGTaccgccacc
AAGGGAGAGGGTCACGCTGGTC) were then designed to
introduce a TAB1 or HCF1 peptide followed by a GGG
linker in place of the PreScission Protease site and the first
two residues of the hOGT, changing the boundaries to
315–1031. This PCR product was introduced into the existing
construct by restriction free cloning [55].
Cloning of the quintuple mutants of hOGT was carried
out by ordering a GeneBlock from Integrated DNA
Technologies containing all five codon changes. This was
then incorporated into the existing construct by restrictionless
cloning based on [55] but using KOD polymerase and
DpnI from Fermentas and using primers OGT5N5A_F:
CCTGTCCGACCCATGCTGATTC, OGT5N5A_R: CCGGAG
TCTTTGTGAATCGATGC and GeneBlock OGT_5N5ACCT
GTCCGACCCATGCTGATTCCCTGgcCgcCCTGGCGAACA
TTAAGCGTGAACAAGGCAACATTGAAGAAGCCGTCCG
TCTGTATCGTAAAGCGCTGGAAGTCTTTCCGGAATTCG
CGGCGGCACATAGTgcCCTGGCCTCCGTGCTGCAGCAA
CAGGGCAAGCTGCAGGAAGCTCTGATGCACTATAAA
GAAGCGATTCGTATCTCTCCGACCTTTGCCGATGCATA
CAGTgcCATGGGTAATACGCTGAAAGAAATGCAAGAC
GTGCAGGGCGCCCTGCAATGTTATACCCGCGCAATTCA
GATCAACCCGGCTTTCGCGGATGCCCATTCAgcTCTGGC
ATCGATTCACAAAGACTCCGG.
The pGEX6P1 TAB1 7-409 construct was generated from a
larger fusion construct produced as above, then the GGG-
hOGT region was erased using a method based on the
QuikChange site-directed mutagenesis kit by Agilent but
using KOD polymerase and DpnI from Fermentas. All inserts
were confirmed by DNA sequencing.4.2. Expression and purification of linear fusion
constructs
Both HCF1PRO:OGT and TAB1:OGT fusion constructs were
recombinantly expressed as His6-tagged proteins in E. coli
BL21 (DE3) pLysS. Cultures were grown in LB media,
supplemented with ampicillin, until an OD600 of approximately
0.6 was reached. Expression was induced with 250 mM IPTG
for 18 h at 168C. Cells were harvested by centrifugation at
4800g in a J6-MI centrifuge (Beckman Coulter). The pellet
was resuspended in lysis buffer (25 mM Tris, 150 mM
NaCl, 0.5 mM TCEP and 30 mM imidazole pH 8.5, contain-
ing approx. 0.1 mg ml21 lysozyme, 0.1 mg ml21 DNAse,
1 mM benzamidine, 0.2 mM PMSF and 5 mM leupeptin).
Cell lysate was spun down at 20 000g for 10 min in an
Avanti J-25 centrifuge (Beckmann). The supernatant was
incubated with Nickel-NTA resin for 2 h at 48C. The beads
were isolated by passing through a column and washed exten-
sively with lysis buffer. Bound protein was eluted from the
beads with lysis buffer containing 200 mM imidazole. The
eluent was diluted to 25 mM NaCl in Tris–HCl pH 8.5 and
purified further by anion-exchange chromatography using a
HiTrap QFF 5 ml column (GE Healthcare). Fractions corre-
sponding to the size of the fusion protein were pooled,
concentrated to less than 2 ml and loaded onto a SuperDex
200 gel filtration column (GE Healthcare). Purity was checked
by subjecting the fractions to SDS-PAGE analysis and pure
fractions were pooled and buffered exchanged into a 50 mM
Tris–HCl pH 8.5, 25 mM NaCl and 0.5 mM TCEP.
4.3. Crystallization and structure solution
The fusion constructs were crystallized at a protein concen-
tration of approximately 10 mg ml21 in the presence of
5 mM UDP. Sitting drop vapour diffusion experiments
were performed by combining 0.5 ml of protein with 0.5 ml
mother liquor. Crystals grew in 2–3 days in 3.5 M
sodium formate, 0.1 M Tris pH 8.5 for TAB1-OGT fusion
and 1.3 M ammonium tartrate dibasic, 0.1 M Tris pH 8.5
for HCF1PRO:OGT. Crystals were cryoprotected using 10%
glycerol in mother liquor and 2.5 M lithium sulfate for
TAB1:OGT and HCF1PRO:OGT, respectively. Data were col-
lected at the European Synchrotron Radiation Facility
(ESRF) beam line ID29 and were autoprocessed with XDS
[56,57]. Structures were solved by molecular replacement
using Molrep [58] and chain A of PDB 3PE4 [30] as search
model. Crystals belong to space groups P6122 (TAB1:OGT)
and P6222 (HCF1PRO:OGT) and have one molecule per
asymmetric unit. A ligand topology for UDP was created
with PRODRG [59]. The structures were fully refined using
iterative cycles of Refmac5 [60] and manual building with
COOT [61]. Data collection and refinement statistics can be
found in the electronic supplementary material, table S1.
4.4. In vitro TAB1 glycosylation assay
For glycosylation assays, TAB1 and hOGT (WT and mutants)
were expressed and purified as described previously
[30,31,33,41]. Ten mircomolar of TAB1 was incubated with
50 nM hOGT (WT or mutants) in TBS reaction buffer (0.1 M
Tris–HCl pH 7.4, 150 mM NaCl) supplemented with
0.5 mM TCEP and 0.1 mg ml21 BSA. The reaction was started
rsob.royalsocietypublishing.org
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7by adding UDP-GlcNAc to a final concentration of 100 mM
and incubating the reaction mixtures at 258C. Ten microlitres
of sample mixtures was taken at indicated times and mixed
with 4x LDS sample loading buffer to a final volume of
50 ml and boiled at 958C for 5 min. Proteins were resolved
using precast SDS-PAGE gels (NuPAGE 4–12% Bis-Tris
gels, Invitrogen) and blotted onto nitrocellulose membranes
(GE Healthcare). The primary antibodies were used at the fol-
lowing concentrations: Anti-TAB1-O-GlcNAc (1 : 1000 [45]),
anti-TAB1 (1 : 1000, Division of Signal Transduction and
Translation, University of Dundee) and anti-OGT (1 : 2000,
DM17, Sigma-Aldrich, Cat#: O6264). Li-Cor secondary anti-
bodies (IRDye 680 Donkey anti-rabbit and IRDye
800 Donkey anti-rabbit, anti-sheep) were used at dilutions
of 1 : 10 000. Blots were imaged using the Li-Cor Odyssey
infrared imaging system (Li-Cor, Lincoln, NE). Quantification
of the O-GlcNAc specific signal (gTAB1) was performed
using imageStudioLite (Li-Core) and normalized to total
OGT (tOGT) and total TAB1 (tTAB1) signal. Data were
plotted with GraphPad PRISM 7.
4.5. Steady-state kinetics
hOGT activity was determined in reactions containing 50 nM
of either WT or 5N5A His6-hOGT (312–1031), 50 mM Tris–
HCl pH 7.4, 0.1 mg ml21 BSA, 10 mM sodium dithionate
and varying concentrations of the TAB1 peptide
KKPVSVPYSSAQSTSKTSVTLSL or at a fixed concentration
of 10 mM of the TAB1 peptide KKPVSVPYSSAQSTS, in a
total volume of 100 ml. Reaction mixtures were preincu-
bated for 15 min before initiating the reaction by adding
UDP-GlcNAc to a final concentration of 50 mM. Reactions
were incubated for 30 min at 218C before addition of
200 ml of 75 mM pyrocatechol violet/15 mM fluorophore,
DP-sensitive xanthene-based Zn(II) compound [33,62,63],
in 25 mM HEPES pH 7.4, 10 mM NaCl, 50% (v/v) MeOH.
UDP formation was detected on a Gemini EM fluorescent
Microplate reader (Molecular Devices) using excitation
and emission wavelengths of 485 nm and 530 nm, respect-
ively. Turnover did not exceed 10% for either substrate.
Data are presented as average of three measurements,
with error bars showing s.e.m. Data were analysed with
GraphPad PRISM 7.
4.6. Western blot analysis of purified TAB1:OGT
Samples of purified TAB1:OGT fusion protein were
incubated for 30 min at 378C in the presence and absence of
approximately 10 mg ml21 CpOGA, a promiscuous bacterialO-GlcNAc hydrolase [64]. Samples were supplemented
with 4x LDS-loading buffer and boiled for 5 min at 958C. A
total of 0.5 mg of each untreated and treated TAB1:OGT
fusion protein were subjected to SDS-PAGE analysis and
transferred onto a nitrocellulose membrane (GE Healthcare),
using a wet-transfer system (Invitrogen). The membrane was
blocked in 5% BSA for 30 min at 218C before incubating with
anti-O-GlcNAc AB (RL2, 1 : 1000, Abcam, catalogue no.
ab2739) and anti-OGT AB (1 : 2000, Abcam, catalogue no.
177941). Li-Cor secondary antibodies IRDye 680 Donkey
anti-mouse (anti-O-GlcNAc) and IRDye 800 Donkey anti-
rabbit (anti-OGT) were used at dilutions of 1 : 10 000. Blots
were imaged using the Li-Cor Odyssey infrared imaging
system (Li-Cor, Lincoln, NE).
4.7. Peptide synthesis
Microwave-assisted solid-phase peptide synthesis was per-
formed with CEM Liberty automated peptide synthesizer
on Rink amide MBHA resin (Novabiochem) using standard
Fmoc chemistry protocols. The peptide was cleaved from
the resin and deprotected with i-Pr3SiH-H2O-TFA 2.5 : 5 :
92.5 mixture for 2 h. The crude peptide was obtained after
dilution of the cleavage mixture with diethyl ether and cen-
trifugation. It was finally purified by reverse-phase HPLC
at C18 Waters Xbridge OBD 5 mm 19  100 column in a
linear gradient of buffer B (acetonitrile20.1% trifluoroacetic
acid) in buffer A (water20.1% trifluoroacetic acid) 5–40%
in 5 min, flow rate 20 ml min21. Appropriate fractions were
pooled and freeze-dried to provide the target compound as
fluffy solid.5. Accession codes
X-ray diffraction data and refined structures have been
deposited in the Protein Data Bank under accession codes
5LWV (HCF1PRO:OGT) and 5LVV (TAB1:OGT).
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